Enliven Therapeutics (NASDAQ:ELVN) Issues Earnings Results, Beats Estimates By $0.09 EPS

Enliven Therapeutics (NASDAQ:ELVN) posted its earnings results on Thursday. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09, FiscalAI reports.

Enliven Therapeutics Trading Up 10.0%

Enliven Therapeutics stock traded up $4.47 during midday trading on Friday, reaching $49.27. 463,354 shares of the stock traded hands, compared to its average volume of 1,300,609. The firm has a market cap of $3.61 billion, a PE ratio of -29.52 and a beta of 0.34. The company has a 50-day simple moving average of $47.48 and a two-hundred day simple moving average of $42.96. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32.

Insider Transactions at Enliven Therapeutics

In other news, Director J. Scott Garland sold 13,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the sale, the director owned 13,000 shares of the company’s stock, valued at approximately $606,710. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 31,054 shares of company stock worth $1,493,823 over the last quarter. Insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the topic of several research analyst reports. JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics in a report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price objective on the stock. Mizuho increased their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. The Goldman Sachs Group boosted their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Thursday, October 15th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.